Microbiome Current Successes
7 active projects, 30 published manuscripts. Their key findings so far:
- People carrying different IBD genes, such as NOD 2, have different compositions of gut bacteria. A person’s genes can therefore affect which gut bacteria they host.
- Different subsets of IBD can be characterized by signature bacterial compositions, defined by risk signature of ~20 microbial families
- A novel way to study intestinal bacterial metabolism in humans have been identified
Microbiome Phase 4 Progress:
- Genes affect bacterial composition
- Viruses play an important role in establishing disease
- 20+ families of bacteria implicated in disease progression
- In 2012, we developed a platform for sharing data between the consortia
- In 2013, we learned that patients who develop stricturing phenotype have certain microbial populations
Ultimate goals for the consortium-
- Understand mechanisms by which bacteria, viruses and fungi cause disease in genetically susceptible hosts. This can lead to new strategies to treat and prevent IBD
- Identify bacteria and viruses associated with flares: This will help guide ways to prevent disease relapses by immunization, antibiotics, dietary modification, probiotics, etc.
- Use bacterial profiles to predict the course of disease in an individual patient with IBD – aggressiveness of disease, risk of complications and response to treatment